CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya ...

Due to the small size and height of the Eva1 molecule, Eva1CAR-T cells can form more effective immune synapses—contact zones between an immune cell and its target tumor cells. The formation of robust ...

A study to look at why long-lived bats do not get cancer has broken new ground about the biological defenses that resist the ...

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

Background: Esophageal squamous cell carcinoma (ESCC) represents a highly aggressive malignancy with poor prognosis and limited therapeutic advancements. While chimeric antigen receptor (CAR)-T-cell ...

CAR T-cells are a type of modified T cells from the immune system, designed to recognize and eliminate cancerous cells, a more selective approach compared to the general killing of infectious ...

In a significant breakthrough, CAR T-cell therapy, which uses patients’ T-cells to fight cancer by re-engineering them, was developed by and infused at the hospital where they were admitted. Normally, ...

CAR T-cell therapies offer high response rates but face logistical challenges, including lengthy "brain-to-vein" times and high costs, limiting their accessibility. Bispecific therapies are more ...